AI stock analysis · Drug Manufacturers - General · Last analyzed Aug 19, 2026
Compass Score
3.0/5
Call
Hold
Price
$1225.73
AI Target
$1310.90 +6.9%
AI Analyst Summary
Eli Lilly's GLP-1 and incretin franchise (Mounjaro/Zepbound) is driving extraordinary 47.7% revenue growth, a pace rarely seen at this market cap, with earnings compounding at 26%+ YoY as manufacturing scale catches up to blockbuster demand. The forward P/E of 25.9x and PEG of 1.48 suggest the market has not yet fully priced in the multi-year earnings power of the obesity and diabetes pipelines. The primary risk is supply-constrained revenue recognition — any manufacturing shortfall or competitor approval could compress near-term estimates and trigger multiple compression on a high-expectation stock.
Catalysts
Continued Zepbound/Mounjaro volume ramp as new manufacturing capacity (Lilly's $9B+ U.S. site investments) comes online, directly unlocking constrained revenue upside in H2 2025 and beyond.
Pipeline readouts for oral GLP-1 candidate orforglipron and tirzepatide expansions into heart failure, sleep apnea, and NASH — positive Phase 3 data could substantially expand the addressable market.
Quarterly earnings beats in upcoming reporting periods driven by continued prescription growth, favorable payer coverage wins, and operating leverage on a rapidly scaling revenue base.
Fundamentals
PeTrailing P/E 41.1x / Forward P/E 25.9x · 3.0/5
Trailing P/E of 41.1x is elevated relative to the broader market but the forward P/E of 25.9x reflects rapidly expanding earnings. Valuation is rich yet increasingly growth-justified given the top-line acceleration.
PegPEG 1.48 · 4.0/5
PEG of 1.48 is reasonable for a large-cap healthcare compounder growing earnings at 26%+ YoY. Well below the threshold that would signal overvaluation given the durability and visibility of the growth runway.
Analyst RatingBuy consensus (1.7) · 4.0/5
23 Buy / 4 Hold / 2 Sell across 28 analysts with a consensus rating of 1.7 reflects broad, high-conviction bullish sentiment. The small dissenting minority does not materially detract from the constructive setup.
Earnings growth of 26.2% YoY paired with 47.7% revenue growth signals a powerful and accelerating top-line to bottom-line conversion. Growth is comfortably above the 25% threshold for a top score and is underpinned by surging demand across key therapeutic franchises.
A perfect 4-for-4 EPS beat rate in recent quarters demonstrates strong near-term execution. Score is capped at 4 rather than 5 due to limited history (only 4 quarters provided vs. the 8-quarter full window).
ManagementConsistent execution with strong capital allocation · 4.0/5
Flawless recent EPS beat record, accelerating revenue growth, and high analyst confidence all point to disciplined management execution. Capital is being effectively deployed to scale high-demand franchises, though the 8-quarter full beat history is not available to warrant a maximum score.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.